


FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
<div style="text-align: center;">  </div> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Arthur M. Krieg	
Sheet 1 of 3				GROUP ART UNIT: 1635	EXAMINER: Jane J. Zara

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A9	2004-0152657	A1	Krieg et al.	08-05-2004
	A9	2004-0162258	A1	Krieg et al.	08-19-2004
	A10	2004-0162262	A1	Krieg et al.	08-19-2004
	A11	2004-0167089	A1	Krieg et al.	08-26-2004
	A12	2004-0171150	A1	Krieg et al.	09-02-2004
	A13	2004-0171571	A1	Krieg et al.	09-02-2004
	A14	2004-0181045	A1	Krieg et al.	09-16-2004
	A15	2004-0198688	A1	Krieg et al.	10-07-2004
	A16	5,804,566		Carson et al.	09-08-1998

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C72	Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
	C73	Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
	C74	Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
	C75	Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	
	C76	Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
	C77	Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
	C78	Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
	C79	Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633(2) and (j)) (Electronically filed, unsigned). September 9, 2004.	
	C80	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	
	C81	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
	C82	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
	C83	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.	
	C84	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.	
	C85	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.	

FORM PTO-1449/A and B (Modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Arthur M. Krieg	
				GROUP ART UNIT: 1635	EXAMINER: Jane J. Zara
Sheet	2	of	3		

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

C85	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.	
C87	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.	
C88	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
C88	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
C88	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
C91	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.	
C92	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
C93	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.	
C94	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
C95	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
C96	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
C97	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	
C98	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
C99	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
C100	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
C101	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	
C102	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
C103	CAPRON et al., Immunologic aspects of schistosomiasis. Annu Rev Med. 1992;43:209-18. Review. Exhibit 2068.	
C104	JILEK et al., Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J Immunol. 2001 Mar 1;166(5):3612-21. Exhibit 2036.	
C105	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract Number 615.	
C106	SANTELIZ et al., Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol. 2002 Mar;109(3):455-62. Exhibit 1041.	
C107	TOKUNGA, Response of the organism to DNA – With a focus on immunostimulatory DNA. Kansen Ensho Meneki. 2001 Autumn; 31(3): 1-12. Japanese. Exhibits 1048 and 1049.	Yes

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

FORM PTO-1449/A and B (Modified) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 09/630,319	ATTY. DOCKET NO.: C1039.70042US00
				FILING DATE: July 31, 2000	CONFIRMATION NO.: 5464
				APPLICANT: Arthur M. Krieg	
				GROUP ART UNIT: 1635	EXAMINER: Jane J. Zara
Sheet	3	of	3		

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

C108	VLASOV et al., Oligonucleotides in cells and in organisms: pharmacological considerations. <i>in</i> Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS. 1991: 243-66.		
C109	WALLNER et al., Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy. 1994 May;49(5):302-8. Review. Exhibit 2028.		
C110	WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. <i>Ann N Y Acad Sci.</i> 1995 Nov 27;772:64-76. Review. Exhibit 2039.		
C111	YAMAMOTO, Cytokine production inducing action of oligo DNA. <i>Rinsho Meneki.</i> 1997; 29(9): 1178-84. Japanese. Exhibits 1050, 1047, and 1046.		Yes
C112	YI et al., "IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides", <i>Journal of Immunology</i> , 156(2): 558-64, 1996. Exhibit 1022.		
C113	ZHANG et al., Antigen- and isotype-specific immune responses to a recombinant antigen-allergen chimeric (RAAC) protein. <i>J Immunol.</i> 1993 Jul 15;151(2):791-9.		
C114	[No Author Listed] DNA is the primary genetic material. <i>in</i> Recombinant DNA, Second Edition. Watson et al., editors. Scientific American Books, New York. p24-5, 147. Exhibit 1003.		
C115	[No Author Listed] Definitions. in <i>The Dictionary of Immunology</i> , Fourth Edition. Herbert et al., editors. Academic Press, 1995. p10. Exhibit 1004.		
C116	[No Author Listed] <a href="http://www.doctorfungus.com/the_fungi/Cryptococcus.htm">http://www.doctorfungus.com/the_fungi/Cryptococcus.htm</a> . Exhibit 1029.		
C117	[No Author Listed] <a href="http://www.doctorfungus.com/the_fungi/Blastomyces.htm">http://www.doctorfungus.com/the_fungi/Blastomyces.htm</a> . Exhibit 1030.		
C118	[No Author Listed] <a href="http://www.doctorfungus.com/the_fungi/Alternaria.htm">http://www.doctorfungus.com/the_fungi/Alternaria.htm</a> . Exhibit 1031.		
C119	[No Author Listed] <a href="http://www.cancer.gov/newscenter/pressreleases/cancervaccines">http://www.cancer.gov/newscenter/pressreleases/cancervaccines</a> . Exhibit 1042.		
C120	[No Author Listed] <a href="http://www.cancer.gov/clinicaltrials/learning/cancervaccines/print">http://www.cancer.gov/clinicaltrials/learning/cancervaccines/print</a> . Exhibit 1043.		
C121	[No Author Listed] Recombinant DNA Technology, in <i>Molecular Biology of the Cell</i> . Alberts et al., editors. Garland Publishing, Inc. 1983. Exhibit 2027.		
C122	[No Author Listed] Definitions. in <i>Dorland's Illustrated Medical Dictionary</i> , Twenty-sixth Edition. W.B. Saunders Company, 1981. Exhibit 2032.		
C123	[No Author Listed] Macromolecules in Prokaryotic and Eukaryotic Cells. in <i>Molecular Cell Biology</i> , Darnell et al., Editors. W.H. Freeman and Company, 1986. Exhibit 2033.		
C124	[No Author Listed] Definitions. in <i>Immunology</i> , Roitt et al., Editors. Gower Medical Publishing Company, 1985. Exhibit 2035.		
C125	[No Author Listed] Definitions. in <i>Webster's New Collegiate Dictionary</i> . The G&C Merriam Company, 1981. p287. Exhibit 2070.		
C126	[No Author Listed] <a href="http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Cancer_Vaccines_Active_Specific_Immunotherapies.asp">http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Cancer_Vaccines_Active_Specific_Immuntherapies.asp</a> . Exhibit 2072.		
C127	[No Author Listed] <a href="http://www.plwc.org/plwc/mainconstructor">http://www.plwc.org/plwc/mainconstructor</a> . Exhibit 2073.		
C128	[No Author Listed] <a href="http://www.icare.org/treatment/tcwtv4.htm">http://www.icare.org/treatment/tcwtv4.htm</a> . Exhibit 2074.		

EXAMINER: /Emily Le/	DATE CONSIDERED: 03/15/2008
-------------------------	--------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]